Research Article

Proapoptotic Role of Potassium Ions in Liver Cells

Zhenglin Xia, Xusen Huang, Kaiyun Chen, Hanning Wang, Jinfeng Xiao, Ke He, Rui Huang, Xiaopeng Duan, Hao Liu, Jinqian Zhang, and Guoan Xiang

1 Third Clinical Medical School of Southern Medical University, Guangzhou 510515, China
2 Department of General Surgery, The Second People’s Hospital of Guangdong Province, Southern Medical University, Guangzhou 510515, China
3 Department of Gastrointestinal Surgery, The Affiliated Hospital, Youjiang Medical University for Nationalities, Guangxi 333000, China
4 Department of Vascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
5 Laboratory Medicine, The Second People’s Hospital of Guangdong Province, Southern Medical University, Guangzhou 510515, China

Correspondence should be addressed to Hao Liu; i191601714@163.com, Jinqian Zhang; jingwanghou@163.com, and Guoan Xiang; guoan_66@163.com

Received 8 November 2015; Revised 29 December 2015; Accepted 7 February 2016

Copyright © 2016 Zhenglin Xia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Potassium channels are transmembrane proteins that selectively promote the infiltration of potassium ions. The significance of these channels for tumor biology has become obvious. However, the effects of potassium ions on the tumor or normal cells have seldom been studied. To address this problem, we studied the biological effects of L02 and HepG2 cells with ectogenous potassium ions. Cell proliferation, cell cycle, and apoptosis rate were analyzed. Our results indicated that potassium ions inhibited proliferation of L02 and HepG2 cells and promoted their apoptosis. Potassium ions induced apoptosis through regulating Bcl-2 family members and depolarized the mitochondrial membrane, especially for HepG2 cell. These biological effects were associated with channel protein HERG. By facilitating expression of channel protein HERG, potassium ions may prevent it from being shunted to procancerous pathways by inducing apoptosis. These results demonstrated that potassium ions may be a key regulator of liver cell function. Thus, our findings suggest that potassium ions could inhibit tumorigenesis through inducing apoptosis of hepatoma cells by upregulating potassium ions transport channel proteins HERG and VDAC1.

1. Introduction

The plasma membrane (PM) ion channels involve almost all of the basic cellular processes and the malignant phenotype of tumor cells. Ion fluxes regulate cell volume and membrane potential through their ion channels and participate in intracellular signal transduction and controlling cell functions. Moreover, in the process of tumorigenesis development, the differences on tumor gene expression levels are determined by ion channels, which may involve, at least in part, a number of pathophysiological features associated with malignant growth [1–3].

In the ion transport molecular family, based on the biochemical structure and highest variability, potassium channels might be the most likely ones to be designed for the targeted therapy of the channel in cancer [4]. It could be used as a new research direction, providing important clues in the development of new therapeutic agents [5]. Thus, the study of ion channel serving as a new target for the diagnosis and treatment of cancer is very important. In this study, we compared the effect of potassium ions in L02 and HepG2 cells and investigated the regulation mechanism of cell functional changes induced by potassium ions.

The differential expressions of potassium channels are frequently observed in different tumors; these differences make tumors have many advantages in biological behaviors [6, 7]. Expression changes are seen in the genome, transcription, translation, or epigenetic level and can also adjust the expression level of potassium channel through the upstream changes in some cases [8, 9]. Some hormones or
growth factors can activate potassium channels and cause abnormal gene expressions of potassium channels [10]. The changes of cell death, proliferation, adhesion, and migration have a significant impact on life activities. All these changes can affect the tumorigenesis. Therefore, interruption of the expression of potassium channels combined with current treatment may significantly improve the treatment of cancer. In short, interfering with potassium channel expression or activity may offer a new therapy for liver cancer [4].

2. Materials and Methods

2.1. Preparation of Plates Coated with Potassium Ions. PBS with different concentrations of potassium ions was prepared and the abbreviations represent K 0 (0 mmol/L), K 25 (3.75 mmol/L), K 50 (7.5 mmol/L), K 75 (11.25 mmol/L), and K 100 (15 mmol/L). The dispersed PBS were added to 6-well plates (3.75 mmol/L), K 50 (7.5 mmol/L), K 75 (11.25 mmol/L), and K 100 (15 mmol/L). The dispersed PBS were added to 6-well plates (add 200 μL per well) or 96-well plates (add 10 μL per well) and then dried at 100°C for 2 hours in air, sterilized by ultraviolet irradiation for half an hour.

2.2. Cell Culture and Treatment. Hepatic cells line L02 cell and hepatoma cells line HepG2 cell were cocultured with different concentrations of potassium ions and cultured in DMEM supplemented with 10% FBS (Gibco, Carlsbad, CA, USA) in 5% CO2 at 37°C.

2.3. Cell Proliferation and Viability. Cell counting kit was purchased from DOJINDO (EQ645; Kumamoto, Japan) to determine cell proliferation. To conduct the assay, L02 (3 × 103) and HepG2 (3 × 103) cells cultured in 96-well plates were treated using the above methods, 10 μL CCK-8 solutions were added to each well. Cells were incubated at 37°C in incubator for 1 hr. A microplate reader (Thermo Scientific, Waltham, PA, USA) was used to detect the absorbance values at 490 nm. Each group consists of five replicates. The data was repeated in five independent experiments and the proliferation of cells was observed at different time points as indicated.

For cell counting, L02 (3 × 103) and HepG2 cells (3 × 103) were added to 6-well plates treated by the above methods with 2 mL of growth medium, and then the cells were observed according to the general protocol by optical microscope. The total cellular scores were counted by cell counter plate after 48 hrs.

2.4. Annexin V-FITC/7-AAD Staining Assay. L02 and HepG2 cells were treated with potassium ions as described in the above method in 6-well plates. The cells were then collected and washed twice with PBS. After centrifugation, cells were resuspended in 100 μL of binding buffer and then stained by Annexin V-FITC/7-AAD (640906/420404; BioLegend, CA, USA) for analysis of the apoptosis of cells.

2.5. Cells Cycle Analysis. L02 and HepG2 cells were cultivated in 6-well plates treated by the above methods and then cultured for 48 hrs. The cells were collected, fixed with 70% ethanol overnight and then resuspended in cold PBS, and then incubated with 1 mg/ml 7-AAD (420404; BioLegend, CA, USA) at 37°C for 15 min. The samples were detected by using FACScalibur flow cytometer (BD Biosciences, San Diego, CA, USA), and the proportions of cells in the GI, S, and G2 phases were investigated by using ModFit LTTM software (BD Biosciences, San Diego, USA).

2.6. Western Blotting and Antibodies. The total protein concentration was detected using the Pierce BCA assay (23225; Thermo Scientific, Waltham, PA, USA) and a microplate reader (Thermo Scientific, Waltham, PA, USA) at 562 nm. Cell lysates were resolved in 10% SDS-PAGE and transferred onto a PVDF membrane (ISEQ0010; Millipore, MA, USA). Target proteins were detected by using specific antibodies. The primary antibodies were used in a 1:1500 dilution. The bands were investigated using the enhanced chemiluminescence system (32209; Thermo Scientific, Waltham, PA, USA). All the data were quantified by using Bio-Profil BioID software (S:1L640150; VILBER, France). The primary antibodies are anti-Bax (sc-493; Santa Cruz, TX, USA), anti-caspase-3 (sc-7148; Santa Cruz, TX, USA), anti-P53 (sc-126; Santa Cruz, TX, USA), anti-HERG (sc-48428; Santa Cruz, TX, USA), anti-VDAC/Porin antibody (ab15895; Abcam, Cambridge, MA), anti-ACSS1 (ab69270; Abcam, Cambridge, MA), anti-Bcl-2 (2870; CST, Danvers, MA, USA), and anti-GAPDH (5174; CST, Danvers, MA, USA).

2.7. Mitochondrial Membrane Depolarization. JC-10 (Enzo Life Sciences, New York, USA) was used to detect the mitochondrial membrane depolarization of cells. The absorbing value of JC-10 lies on the polarization level of mitochondrial membrane. Hyperpolarized mitochondria was complicated with higher absorbent of JC-10 compared to depolarization. After treatment, L02 and HepG2 cells were washed once with PBS and then incubated with 500 μL of JC-10 dye-loading solution for 40 minutes. After incubation, the cells were subjected to flow cytometry.

2.8. Caspase-3/7 Activity Assay. L02 and HepG2 cells were cultured in 96-well plates treated by the above methods and incubated for 48 hrs. After the treatment with potassium ion, caspase-3/7 activity in liver cells was analyzed using caspase-Glo 3/7 assay kit.

2.9. Statistics. All data were showed as mean ± SD, from at least three averaged replicates of independent experiments. Statistical comparison of quantitative data in the group was determined by one way ANOVA or Student’s t-test. To determine differences between groups not normally distributed, medians were compared using Kruskal-Wallis analysis of variance. SPSS 19.0 software (SPSS Inc., Chicago, USA) was used for data analysis. P < 0.05 was regarded as statistically significant.

3. Results

3.1. The Potassium Ions Inhibited Cell Proliferation in L02 and HepG2 Cells. To examine the effects of potassium ions on cell proliferation, cells were treated with increasing
concentrations of potassium for indicated time points. By the CCK-8 assay, the results showed that potassium ions could inhibit the proliferation of L02 (Figure 1(a)) and HepG2 cells (Figure 1(b)), especially for HepG2 cells. The inhibition was both time and dose dependent. The proliferation of L02 cells cocultured with potassium ions decreased obviously after culture for 48 hrs \( (P < 0.05) \). The proliferation of HepG2 cells cocultured with potassium ions decreased especially at 48 hrs. On the other hand, cell growth was quantified with total cell count. L02 and HepG2 cells were added to 6-well plates treated by the above methods and cultured for 48 hrs. As shown in Figure 1, the cell count for L02 (Figure 1(c)) and HepG2 (Figure 1(d)) was low with increasing concentration of potassium ions. The decreasing trend is more obvious for HepG2 than L02 cells.

3.2. Potassium Ions Affected the Cells Cycle of L02 and HepG2.

To test the effects of potassium ions on the cell cycle of L02 and HepG2 cells, we conducted flow cytometry assay. The results indicated that the effects of potassium ions on cell cycle of L02 cells (Figure 2(a)) and HepG2 cells (Figure 2(b)) were dose dependent. The cell number of the S phase in L02 and HepG2 cells both decreased, while it increased significantly in G2/M phase. These results demonstrated that
potassium ions could arrest cell cycle at S phase and suppress the growth of L02 and HepG2 by preventing proper DNA replication. And the arrest is more significant for HepG2 than L02 cells.

3.3. Potassium Ion Induces Apoptosis of L02 and HepG2 Cells through Regulating Antiapoptotic Bcl-2 Family Members and Mitochondrial Proteins and Potassium Channel Related Protein. After being cocultured with potassium ions for 48 hrs, Annexin V-FITC/7-AAD staining was performed. And the numbers of Annexin V positive cells increased significantly. The results showed that the Annexin V positive cells of L02 (Figures 3(a) and 3(b)) and HepG2 (Figures 3(c) and 3(d)) both increased in a concentration dependence manner, especially for HepG2 cells.

As shown in Figure 4(a), the expression level of Bcl-2 downregulated in L02 cells, but Bax and caspase-3 upregulated. We could see the same trends in HepG2 cells (Figure 4(c)), but the trends are more obvious than those in L02 cell. Moreover, in K 100 group, the expression levels of Bax and caspase-3 downregulated. We determined the Bcl-2/Bax ratio in L02 (Figure 4(b)) and HepG2 cells (Figure 4(d)) at the protein level, which increased significantly in a concentration dependence manner, especially for HepG2 cells. They may be responsible for the apoptosis induced by potassium ions observed in L02 and HepG2 cells.

We performed caspase-3/7 activation detection to identify the apoptotic role of potassium ions on L02 and HepG2 cells. Potassium ions induced obvious activation of caspase-3/7 activity in L02 (Figure 5(a)) and HepG2 cells (Figure 5(b)). In summary, the findings demonstrated that potassium ions could reduce cell viability, promote cell apoptosis, and increase caspase-3/7 activity of L02 and HepG2 cells. This is more obvious in HepG2 cells than L02 cells.

In order to assess mitochondrial and potassium channel related genes expression changes, levels of mitochondria related proteins, VDAC1 and ACSS1, and potassium channel related protein HERG were evaluated after treatment of liver cells with potassium ions. As shown in Figures 4(a) and 4(c), the expression of ACSS1 downregulated in a dose-dependent manner, and the expression of VDAC1 and HERG upregulated, especially for HepG2 cells.

3.4. Potassium Ions Depolarized the Mitochondrial Membrane of L02 and HepG2 Cells. We used JC-10 to measure the mitochondrial membrane polarization in L02 and HepG2 cells. The results showed that the ratios of red to green fluorescence were significantly lower in potassium ions treated L02 cells (Figure 6(a)) and HepG2 cells (Figure 6(b)). And the results demonstrated mitochondrial membrane potential depolarized after exposure to potassium ions in liver cells. Moreover, these changes indicated mitochondrial membrane potential of liver cells depolarized in a concentration dependence manner after exposure to potassium ions, especially for HepG2 cells.

4. Discussions

Hepatocellular carcinoma (HCC) is a common malignant tumor of liver, usually in individuals with developing chronic liver disease or cirrhosis. HCC is the common cause of cancer and is ranked fifth while it is also the second commonest
Figure 3: Continued.
cause of cancer deaths among human [11]. Patients with HCC have poor prognosis; thus urgent measures to curb HCC are needed [12–14].

The hallmarks of tumor contain the inhibition of programmed cell death and abnormal cell proliferation [2]. Exploring new strategies to induce apoptosis and inhibit proliferation of tumor cells is needed. Researchers found that the first features of potassium channels in nonneural cells were the role of proliferation [1, 2]. Our research also showed that potassium ions could inhibit proliferation of liver cells, especially for HepG2 cells. Moreover, the results of cells cycle analysis indicated that potassium ions could block the S phase of the cell cycle and suppress the growth of L02 and HepG2 cells through preventing proper DNA replication. The antitumor influence of potassium ions has been proved in most human tumor cells through regulation of cell cycle and apoptosis [15, 16]. Inhibition of apoptosis can result from carcinogenesis, so induction of apoptosis may be a better potential antitumor therapeutic strategy [17–20]. However, effects of potassium ions on hepatocellular carcinoma have not been reported. Our results identified that potassium ions promoted cell apoptosis and induced obvious activation of caspase-3/7 activity in both L02 and HepG2 cells, especially for HepG2 cells. Therefore, the specific mechanisms need to be deeply investigated.

Apoptosis is an important mechanism for eliminating both excess normal cells and those cells which have sustained damage. The two common pathways of apoptosis are exogenous (death receptor mediated) and intrinsic (mitochondrial) approach [21, 22]. Potassium channel is the important factor for the changes in membrane potential during the cell-cycle progression. Therefore, blocking the activity of potassium channels could induce antiproliferation effects [23, 24]. Concomitantly, at the initiation of apoptosis, intracellular potassium ions concentration decreased. Potassium channel is a key channel to maintain the stability of cell membrane potential. Because there are many types of these channels mediating dominant potassium efflux, they play a significant role in membrane permeability and cell volume regulation [25, 26]. The tumor cells with negative resting potential are usually smaller than normal cells [27]; thus, inflow of more potassium ions through high level expression of potassium channels in response to the certain physical process is possible. Our results demonstrated that the mitochondrial pathway of apoptosis is important. After being treated with potassium ions for 48 hrs, mitochondrial membrane potential (ΔΨm) of HepG2 and L02 cells both decreased, which explained potassium ions induced apoptosis of HepG2 and L02 cells. Potassium ions may inhibit cell-cycle progression and proliferation through reducing the production of ATP and mitochondrial membrane depolarization.

In addition to supplying cellular energy, mitochondria are involved in other tasks, such as signaling, cellular differentiation, and cell death, as well as maintaining control of cell cycle and cell growth. Mitochondrion is an important factor controlling the intrinsic pathway of cell apoptosis, including release of caspase cofactors, such as cytochrome c (Cyt c) and SMAC, generation of apoptotic body, and induction of apoptosis. Furthermore, the Bcl-2 gene family is a key point of the mitochondria pathway [28]. This pathway involves several members including Bax, a proapoptotic protein, and Bcl-2, an antiapoptotic protein, which played a crucial role in regulation of apoptosis [29, 30]. The Bcl-2/Bax ratio has been used to evaluate the cell apoptosis, and its reduction could activate the expression of caspase proteins [31, 32]. By Western Blot detection, we found that Bcl-2/Bax ratio in liver cells decreased after being cocultured with potassium ions for 48 hrs. These data showed that the decrease of the ratio is closely related to liver cells apoptosis induced by potassium ions.

Voltage-dependent anion-selective channel protein 1 (VDAC1) is a voltage-dependent anion channel which is
Figure 4: Potassium ions affected expression of apoptosis-related proteins and mitochondrial proteins of liver cells. The expression levels of P53, apoptosis-related proteins Bax, Bcl-2, caspase-3, or mitochondrial protein VDAC1, ACSS1, and K+$^+$ channel protein HERG in liver cells were determined by Western Blotting. (a) In L02 cells, the levels of Bax, caspase-3, VDAC1, and HERG increased after being cocultured with different concentrations of potassium ions in a dose-dependent manner, and the level of Bcl-2 decreased in a dose-dependent manner. The expression level of ACSS1 has no obvious change. (b) The Bcl-2/Bax ratios in L02 cells ($P < 0.05$) showed as relative optical density values of the protein bands normalized to GAPDH decreased in a dose-dependent manner. (c) In HepG2 cells, the expression levels of Bax, caspase-3, VDAC1, and HERG increased after being cocultured with different concentrations of potassium ions in a dose-dependent manner, and the expression level of Bcl-2 and ACSS1 decreased in a dose-dependent manner. Both the increasing and decreasing trends were more obvious than those in L02 cells. (d) The Bcl-2/Bax ratios in HepG2 cells ($P < 0.05$) showed as relative optical densities of the protein bands normalized to GAPDH decreased in a dose-dependent manner and more obviously than in L02 cells. All data are represented as mean ± SEM. $^*P < 0.05$.

involved in the regulation of cell metabolism, mitochondrial apoptosis, and spermatogenesis. VDAC1, mitochondrial porin 1, played a pivotal role in mitochondria mediated apoptosis and transporting various ions or small molecules across the outer mitochondrial membrane. In particular, VDAC1 is the major ion transport channel and is implicated in cancer. The increasing expression of VDACs may be a specific target for treatment of cancer [33]. HK2 binding to VDAC antagonizes cell apoptosis through inhibition of Bax-induced releasing of Cyt c [7, 34, 35] and inhibits the mitochondrial permeability transition [36]. The decomposition product of HK seems to destroy aerobic glycolysis
and energy balance of cells, regulate the interaction of Bcl-2 protein family, and promote mitochondrial VDAC oligomer formation to induce cell death [37, 38]. Thus, the HK-VDAC complex has become an important target for treatment of cancer [39, 40]. Our results showed that potassium ions upregulated the expression of VDAC1 in a dose-dependent manner. Therefore, potassium ions overbalanced the mitochondrial membrane potential through upregulating VDAC1 or breaking the balance of Bcl-2/Bax ratio and then induced Cyt c released from mitochondria, caspase activation, and caspase-3/7 ration imbalance, finally resulting in cell apoptosis.

Figure 5: Potassium ions induced activation of caspase-3/7 activity in liver cells. (a) Potassium ions induced activation of caspase-3/7 activity in L02 cells. (b) Potassium ions induced activation of caspase-3/7 activity in HepG2 cells, too. All data are represented as mean ± SEM. * P < 0.05, ** P < 0.01.

Figure 6: Potassium ions depolarized the mitochondrial membrane potential in liver cells. We measured mitochondrial membrane polarization in L02 and HepG2 cells at 48 hrs using JC-10. The ratio of red to green fluorescence decreased significantly in both L02 and HepG2 cells treated with potassium ions compared to control. (a) In L02 cells, the ratios of red to green fluorescence decreased in a dose-dependent manner (P < 0.05). (b) In HepG2, the ratios decreased in a dose-dependent manner cells and more obviously than in L02 cell (P < 0.05). All data are represented as mean ± SEM. * P < 0.05, ** P < 0.01.
Another protein ACSS1 was detected, which is the key protein in mitochondrial respiratory chains and encodes a mitochondrial acetyl-CoA synthetase that it used to produce ATP molecules. Our results indicated that potassium ions induced downregulation of ACSS1, and then mitochondrial energy metabolism was restrained. It caused a reduction of cell proliferation and cell-cycle arrest. Both the mitochondrial membrane depolarization and metabolic disorders are the suppressor of cell cycle. The expression of ACSS1 in HepG2 cells downregulated after being cocultured with potassium ions, but there was no difference in L02 cells. It demonstrated that potassium ions could destroy the mitochondrial respiratory chains and restrain the mitochondrial energy metabolism. Moreover, for the differences between L02 and HepG2 cell, ACSS1 may play a crucial role.

In order to further evaluate the gene expressions change related to potassium channel induced by potassium ions in L02 and HepG2 cells, the expression of HERG was evaluated. HERG is a gene (KCNH2) that encodes a protein known as Kv11.1, the alpha subunit of a potassium ions channel [41]. HERG involves regulation of nervous system functions and also carcinogenesis and development of leukemia tumor [41]. The expression levels of HERG in liver cells upregulated, especially for HepG2 cells. The results indicated that these biological functions affected by potassium ions were associated with channel protein HERG.

It is known that potassium ions play an extensive role. We studied the biological function induced by potassium ions in liver cells and explored their molecular mechanism. By facilitating expression of channel protein HERG, potassium ions may prevent cells from being shunted to procarcinous pathways and overbalance the mitochondrial membrane potential through upregulating expression of VDAC1 or breaking the balance of Bcl-2/Bax ratio and then induced cytochrome c released from mitochondria, caspase activation, and caspase-3/7 ratio imbalance, finally resulting in cell apoptosis.

In conclusion, our results demonstrated that potassium ions may be a key regulator of liver cell function. Potassium ions could inhibit tumorigenesis through inducing apoptosis of hepatoma cells by upregulating potassium ions transport channel proteins HERG and VDAC1.

Competing Interests
The authors declare that there are no competing interests.

Authors’ Contributions
Zhenglin Xia and Xusen Huang contributed equally to this work.

Acknowledgments
This work was supported by grant from the National Natural Science Foundation of China (no. 81071990), Natural Science Foundation of Guangdong Province (no. 5201201008279), Science and Technology Planning Project of Guangdong Province (no. 2012A030400055, no. 2010B080701088, no. 2011B08070196, no. 2011B031800184, and no. 2012B03180411), and Science and Technology projects of Guangzhou (no. 2011J410010).

References
[1] D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646–674, 2011.
[2] D. Urrego, A. P. Tomczak, E. Zahed, W. Stühmer, and L. A. Pardo, "Potassium channels in cell cycle and cell proliferation," Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 369, no. 1638, Article ID 20130094, 2014.
[3] T. E. DeCoursey, K. G. Chandy, S. Gupta, and M. D. Cahalan, "Voltage-gated K⁺ channels in human T lymphocytes: a role in mitogenesis?" Nature, vol. 307, no. 5950, pp. 465–468, 1984.
[4] L. A. Pardo and W. Stühmer, "The roles of K⁺ channels in cancer," Nature Reviews Cancer, vol. 14, no. 1, pp. 39–48, 2014.
[5] H. Wulf, N. A. Castle, and L. A. Pardo, "Voltage-gated potassium channels as therapeutic targets," Nature Reviews Drug Discovery, vol. 8, no. 12, pp. 982–1001, 2009.
[6] S. Pillozzi, M. Masselli, E. De Lorenzo et al., "Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers," Blood, vol. 117, no. 3, pp. 902–914, 2011.
[7] R. Zhang, P. Tian, Q. Chi et al., "Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer," Oncology Reports, vol. 27, no. 2, pp. 433–440, 2012.
[8] H. Usman and M. K. Mathew, "Potassium channel regulator KCNRG regulates surface expression of Shaker-type potassium channels," Biochemical and Biophysical Research Communications, vol. 391, no. 3, pp. 1301–1305, 2010.
[9] M. Brevet, D. Fucks, D. Chatelain et al., "Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of Kv1.3 gene promoter methylation," Pancreas, vol. 38, no. 6, pp. 649–654, 2009.
[10] M. Sciaccaluga, B. Fioretti, L. Catacuzzeno et al., "CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca²⁺-activated K⁺ channel activity," American Journal of Physiology-Cell Physiology, vol. 299, no. 1, pp. C175–C184, 2010.
[11] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, "Cancer statistics, 2009," CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009.
[12] L. A. Pardo, "Potassium channels in cell cycle and cell proliferation," Nature Reviews Drug Discovery, vol. 8, no. 3, pp. 257–268, 2009.
[13] Y. Lei, H. Liu, Y. Yang et al., "Interaction of LHBs with C53 promotes hepatocyte mitotic entry: a novel mechanism for HBV-induced hepatocellular carcinoma," Oncology Reports, vol. 27, no. 1, pp. 151–159, 2012.
[14] H. Wang, H. Liu, K. Chen et al., "SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling," Oncology Reports, vol. 28, no. 1, pp. 311–318, 2012.
[15] Z. Feng, H. Li, S. Liu, J. Cheng, G. Xiang, and J. Zhang, "FAM172A induces S phase arrest of HepG2 cells via Notch 3," Oncology Reports, vol. 29, no. 3, pp. 1154–1160, 2013.
[16] J.-W. Jeong, C.-Y. Jin, C. Park et al., "Induction of apoptosis by cordycepin via reactive oxygen species generation in human
leukemia cells,” Toxicology in Vitro, vol. 25, no. 4, pp. 817–824, 2011.
[17] N. Kang, J.-H. Zhang, F. Qiu, S.-I. Tashiro, S. Onodera, and T. Ikemoto, “Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways,” Cancer Letters, vol. 294, no. 2, pp. 147–158, 2010.
[18] P. N. Kelly and A. Strasser, “The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy,” Cell Death and Differentiation, vol. 18, no. 9, pp. 1414–1424, 2011.
[19] A. Strasser, S. Cory, and J. M. Adams, “Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases,” The EMBO Journal, vol. 30, no. 18, pp. 3667–3683, 2011.
[20] S. L. Spencer and P. K. Sorger, “Measuring and modeling apoptosis in single cells,” Cell, vol. 144, no. 6, pp. 926–939, 2011.
[21] N. Lynam-Lennon, S. G. Maher, and J. V. Reynolds, “The roles of microRNA in cancer and apoptosis,” Biological Reviews, vol. 84, no. 1, pp. 55–71, 2009.
[22] W. Hu and J. J. Kavanagh, “Anticancer therapy targeting the apoptotic pathway,” The Lancet Oncology, vol. 4, no. 12, pp. 721–729, 2003.
[23] E. Klimatcheva and W. F. Wonderlin, “An ATP-sensitive K current that regulates progression through early G1 phase of the cell cycle in MCF-7 human breast cancer cells,” Journal of Membrane Biology, vol. 171, no. 1, pp. 35–46, 1999.
[24] D. J. Blackiston, K. A. McLaughlin, and M. Levin, “Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle,” Cell Cycle, vol. 8, no. 21, pp. 3527–3536, 2009.
[25] S. Fulda, L. Galluzzi, and G. Kroemer, “Targeting mitochondria for cancer therapy,” Nature Reviews Drug Discovery, vol. 9, no. 6, pp. 447–464, 2010.
[26] N. Yagoda, M. von Rechenberg, E. Zaganjor et al., “RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels,” Nature, vol. 447, no. 7146, pp. 864–868, 2007.
[27] A. A. Marino, I. G. Iliev, M. A. Schwalke, E. Gonzalez, K. C. Marler, and C. A. Flanagan, “Association between cell membrane potential and breast cancer,” Tumor Biology, vol. 15, no. 2, pp. 82–89, 1994.
[28] A. Burlacu, “Regulation of apoptosis by Bcl-2 family proteins,” Journal of Cellular and Molecular Medicine, vol. 7, no. 3, pp. 249–257, 2003.
[29] M. C. Wei, W.-X. Zong, E. H.-Y. Cheng et al., “Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death,” Science, vol. 292, no. 5517, pp. 727–730, 2001.
[30] J. Lindsay, M. D. Esposti, and A. P. Gilmore, “Bcl-2 proteins and mitochondria—specificity in membrane targeting for death,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1813, no. 4, pp. 532–539, 2011.
[31] L. D. Walensky, “BCL-2 in the crosshairs: tipping the balance of life and death,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1339–1350, 2006.
[32] X.-A. Wang, S.-S. Xiang, H.-F. Li et al., “Cordycepin induces s phase arrest and apoptosis in human gallbladder cancer cells,” Molecules, vol. 19, no. 8, pp. 11350–11365, 2014.
[33] C. Grills, P. V. Jitshen, J. Blayney, S.-D. Zhang, and D. A. Fennell, “Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer,” PLoS ONE, vol. 6, no. 1, Article ID e14635, 2011.
[34] A. Wolf, S. Agnihotri, J. Micallef et al., “Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme,” Journal of Experimental Medicine, vol. 208, no. 2, pp. 313–326, 2011.
[35] J. G. Pastorino, N. Shulga, and J. B. Hoek, “Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis,” The Journal of Biological Chemistry, vol. 277, no. 9, pp. 7610–7618, 2002.
[36] F. Chiara, D. Castellaro, O. Marin et al., “Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels,” PLoS ONE, vol. 3, no. 3, Article ID e1852, 2008.
[37] M. C. Shoshan, “3-bromopyruvate: targets and outcomes,” Journal of Bioenergetics and Biomembranes, vol. 44, no. 1, pp. 7–15, 2012.
[38] V. Shoshan-Barmatz and M. Golan, “Mitochondrial VDAC1: function in cell life and death and a target for cancer therapy,” Current Medicinal Chemistry, vol. 19, no. 5, pp. 714–735, 2012.
[39] L. Galluzzi, O. Kepp, N. Tjeddine, and G. Kroemer, “Disruption of the hexokinase-VDAC complex for tumor therapy,” Oncogene, vol. 27, no. 34, pp. 4633–4635, 2008.
[40] E. Simamura, H. Shimada, T. Hatta, and K.-I. Hirai, “Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents,” Journal of Bioenergetics and Biomembranes, vol. 40, no. 3, pp. 213–217, 2008.
[41] M. C. Sanguinetti and M. Tristani-Firouzi, “hERG potassium channels and cardiac arrhythmia,” Nature, vol. 440, no. 7083, pp. 463–469, 2006.